ZFP36L1 promotes non‐small cell lung cancer progression under hypoxia by modulating CXCL9:SPP1 polarity: A single‐cell transcriptomic study
Clinical and Translational Medicine · 2026-04 · 16 (4)
DOI: 10.1002/ctm2.70642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 29.03.2026. Verfasst von Lijie Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemokine CXCL9, Osteopontin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Program of Zhejiang, Research Center for Lung Tumour Diagnosis and Treatment of Zhejiang Province.
Abstract (Originalsprache)
Background
Non‐small cell lung cancer (NSCLC) is the predominant lung cancer subtype with high mortality rate. Drug resistance and immune evasion limit its therapeutic outcomes. Specific mechanism of the oncogenic ZFP36L1 in NSCLC remains unclear. Methods scRNA‐seq data were analysed using bioinformatic approaches. Hypoxia‐induced alterations in the macrophage CXCL9:SPP1 ratio were assessed by qRT‐PCR, Western blot (WB), immunofluorescence, flow cytometry and ELISA. Dual‐luciferase reporter and ChIP assays were used to validate ZFP36L1‐mediated transcriptional regulation of SPP1. In a co‐cultivation system of macrophages and NSCLC cells, tumour cell malignancy was evaluated through flow cytometry, CCK‐8, Transwell, colony formation and scratch assays. Patient‐derived organoids co‐cultured with macrophages were analysed via H&E, EdU and CellTiter‐Glo assays for pathological changes, proliferation and viability, as well as qRT‐PCR and WB for the expression of apoptosis‐related proteins. Finally, through a macrophage‐specific ZFP36L1‐knockout mouse model, the function of ZFP36L1 in CXCL9:SPP1 polarity and NSCLC progression was validated in vivo.
Results
Hypoxia induced an imbalanced macrophage CXCL9:SPP1 ratio, with more pro‐tumour SPP1 + macrophages and fewer anti‐tumour CXCL9 + macrophages. Upregulation of ZFP36L1 promoted macrophage polarisation towards the SPP1 + phenotype, which then bound to CD44 on tumour cells to accelerate NSCLC progression.
Conclusion
Under hypoxia, ZFP36L1 transcriptionally regulates SPP1 to reduce the macrophage CXCL9:SPP1 ratio, thereby driving NSCLC malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
ORCID-Profile: Weiyu Shen
Förderung
- Key R&D Program of Zhejiang
- Research Center for Lung Tumour Diagnosis and Treatment of Zhejiang Province
Zitieren
APA
Wang, L., Chen, B., He, J., Lin, C., Shen, W., Lv, W., Wang, L., & Hu, J. (2026). ZFP36L1 promotes non‐small cell lung cancer progression under hypoxia by modulating CXCL9:SPP1 polarity: A single‐cell transcriptomic study. Clinical and Translational Medicine, 16(4). https://doi.org/10.1002/ctm2.70642
Vancouver
Wang L, Chen B, He J, Lin C, Shen W, Lv W, et al. ZFP36L1 promotes non‐small cell lung cancer progression under hypoxia by modulating CXCL9:SPP1 polarity: A single‐cell transcriptomic study. Clinical and Translational Medicine. 2026;16(4). doi:10.1002/ctm2.70642
BibTeX
@article{Wang2026,
author = {Wang, Lijie and Chen, Biao and He, Jinxian and Lin, Chengbin and Shen, Weiyu and Lv, Wang and Wang, Luming and Hu, Jian},
title = {ZFP36L1 promotes non‐small cell lung cancer progression under hypoxia by modulating CXCL9:SPP1 polarity: A single‐cell transcriptomic study},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {4},
doi = {10.1002/ctm2.70642}
}
EUVIMED